Form 4: ADIAL PHARMACEUTICALS COO Tony Goodman Granted 94,000 Stock Options

ADIAL Pharmaceuticals, Inc. Chief Operating Officer and Director Tony Goodman was granted 94,000 stock options with an exercise price of $0.688 per share, vesting over 36 months.

Summary

• Tony Goodman, Chief Operating Officer and Director of ADIAL PHARMACEUTICALS, INC. (ADIL), was granted 94,000 stock options.
• The options have an exercise price of $0.688 per share.
• The options will vest pro rata on a monthly basis over 36 months, commencing May 29, 2025.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Mr. Goodman beneficially owns 94,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates executive alignment with shareholder interests through equity compensation, a standard and generally favorable practice.

Positives

• The grant of stock options to a key executive like the Chief Operating Officer aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the executive.

Risks

• The value of the stock options is dependent on the future stock price of ADIAL PHARMACEUTICALS, INC. exceeding the exercise price of $0.688, meaning the options could expire worthless if the stock price does not appreciate.
• Future exercise of these options could lead to dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Future Outlook

The stock options are designed to incentivize the Chief Operating Officer over a 36-month vesting period, aligning his future performance with the company's long-term success and stock price appreciation.

Management Comments

• Tony Goodman is identified as both a Director and the Chief Operating Officer of ADIAL PHARMACEUTICALS, INC.

Industry Context

The grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate key talent by linking their financial incentives to the company's stock performance. This practice is particularly prevalent in growth-oriented sectors where long-term value creation is a primary objective.

Comparison to Industry Standards

• Granting stock options to executive officers is a standard compensation practice across the biotechnology and pharmaceutical sectors, aiming to align management incentives with shareholder value.
• The 10-year term for the options is typical for long-term incentive plans in the industry.
• The vesting schedule over 36 months is also a common approach to ensure executive retention and sustained performance over a multi-year period.

Related Party Transactions

• The grant of 94,000 stock options to Tony Goodman, an officer and director of ADIAL PHARMACEUTICALS, INC., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the interests of the Chief Operating Officer with shareholders, potentially leading to better long-term performance. However, future exercise of these options could result in minor dilution.
• Employees: This compensation structure may serve as a benchmark or incentive for other key employees within the company.

Next Steps

• The stock options will vest pro rata on a monthly basis over the next 36 months, commencing May 29, 2025.
• Tony Goodman may choose to exercise the vested options at any point before their expiration date of May 28, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

ADIAL PHARMACEUTICALS, ADIL, Stock Option, Executive Compensation, Insider Transaction, Form 4, Tony Goodman, Beneficial Ownership, Equity Incentive